Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

BCR signaling pathway inhibitor DZD8586

An inhibitor of the B-cell antigen receptor (BCR) signaling pathway, with potential antineoplastic activity. Upon administration, BCR signaling pathway inhibitor DZD8586 blocks signaling through the BCR signaling pathway. This prevents the proliferation of malignant B cells in which the BCR signaling pathway is overactivated. DZD8586 is able to cross the blood-brain barrier (BBB) and thus potentially useful in the treatment of central nervous system (CNS) metastases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:DZD 8586
DZD-8586
DZD8586
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search